Z. Černá
Charles University in Prague
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Z. Černá.
Leukemia | 2010
Jan Stary; Yahia Jabali; J Trka; Ondřej Hrušák; P. Gajdoš; Hana Hrstková; J Sterba; B Blazek; J. Hak; Dagmar Procházková; Z. Černá; Petr Smisek; Petr Sedlacek; V. Vávra; Vladimír Mihál; O. Hrodek
Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic
Haematologica | 2011
Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimír Mihál; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Z. Černá; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Background Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04–8,293-fold). A greater involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (P=0.003) and with enlargement of the spleen (P=0.0004) and liver (P=0.05). At day 15, a level of minimal residual disease in blood lower than 10−4 was associated with an excellent 5-year relapse-free survival in 78 investigated patients (100% versus 69±7%; P=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15 (high-risk: ≥10−2, intermediate-risk: <10−2 and ≥10−4, standard-risk: <10−4) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point analyses were predictive of outcome in peripheral blood, except for a weak association at day 8. Conclusions Minimal residual disease in peripheral blood at day 15 identified a large group of patients with an excellent prognosis and added prognostic information to the risk stratification based on minimal residual disease at day 33 and week 12.
Memo – Magazine of European Medical Oncology | 2011
Jan Starý; Vladimír Mihál; Petr Smisek; Bohumír Blažek; Yahia Jabali; Hana Hrstková; J. Hak; Daniela Prochazkova; Z. Černá; Jaroslav Štěrba; Jan Trka; Ondřej Hrušák; Jan Zuna; Ester Mejstříková; Iveta Janotova; Petr Sedlacek; H. Ptoszková; Dagmar Pospisilova; Kateřina Toušovská; Pavel Timr; V. Vávra; Katerina Zdrahalova; Lucie Sramkova; Zuzana Zemanova; M. Jarošová; P. Gajdoš; O. Hrodek
Blood | 2009
Ester Mejstrikova; Vendula Pelkova; Michaela Reiterová; Martina Sukova; Zuzana Zemanova; Elena Vodickova; Vit Campr; Kyra Michalova; Marie Jarosova; Renata Formankova; Petr Smisek; Petr Sedlacek; Dagmar Pospisilova; Vladimír Mihál; Jiri Hak; Yahia Jabali; Jaroslav Sterba; Jan Blatny; Ondrej Zapletal; Z. Černá; Tomas Votava; Daniela Prochazkova; Jan Trka; Jan Stary; Ondrej Hrusak
Transfuze a hematologie dnes | 2012
Jana Volejnikova; Ester Mejstříková; Lucie Slamova; Vladimír Mihál; Jaroslav Štěrba; Yahia Jabali; Daniela Prochazkova; Bohumír Blažek; Jiří Hak; Z. Černá; Ondřej Hrušák; Jan Starý; J Trka; Eva Froňková; V. Mihál
Transfuze a hematologie dnes | 2011
Katerina Zdrahalova; Petr Sedlacek; P. Smíšek; Petra Keslova; Jaroslav Štěrba; Hana Hrstková; Bohumír Blažek; Vladimír Mihál; J. Hak; Daniela Prochazkova; Z. Černá; Pavel Timr; Zuzana Zemanová; M. Jarošová; Alexandra Oltová; Jiří Schwarz; Šárka Pospíšilová; Ester Mejstříková; Ondřej Hrušák; Jan Zuna; Elena Vodickova; A. Zámková; Jan Blatný; Ondřej Zapletal; V. Vávra; Iveta Janotova; Jan Starý
Archive | 2011
Jan Starý; Jaroslav Štěrba; Vladimír Mihál; Bohumír Blažek; Yahia Jabali; Z. Černá; Daniela Prochazkova; J. Hak; Petr Sedlacek; Ester Mejstříková; Jan Zuna; Iveta Janotova; Ondřej Hrušák; J Trka
Hematologica - The Hematology Journal | 2011
Jana Volejnikova; Ester Mejstříková; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimír Mihál; Jaroslav Štěrba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Z. Černá; Ondrej Hrusak; Jan Stary; J Trka; Eva Fronkova
Archive | 2010
Jan Starý; Jaroslav Štěrba; Vladimír Mihál; Bohumír Blažek; Yahia Jabali; Z. Černá; Daniela Prochazkova; J. Hak; Petr Sedlacek; Ester Mejstříková; Ondřej Hrušák
Hematologica - The Hematology Journal | 2010
Kateřina Mejstříková; Jana Volejnikova; Eva Froňková; Katerina Zdrahalova; Tomáš Kalina; Jaroslav Štěrba; Yahia Jabali; Vladimír Mihál; Bohumir Blazek; Z. Černá; Daniela Prochazkova; Jiří Hak; Zuzana Zemanová; M. Jarošová; Alexandra Oltová; Petr Sedlacek; Jiří Schwarz; Jan Zuna; J Trka; Jan Stary; Ondřej Hrušák